Enabling the European Nanomedicine Area until 2020 (NANOMED2020)
Enabling the European Nanomedicine Area until 2020
Start date: Sep 1, 2012,
End date: Feb 28, 2014
Nanotechnology applied to medical applications, Nanomedicine, is one of the most important emerging areas of health research and is understood to be the most promising out of the six KETs, for innovative devices and materials for personalised, targeted and regenerative medicine. However, due to the complexity of technologies and medical application areas Nanomedicine requires many different so far independent stakeholders from academia, industry and regulatory bodies. Due to the diversity of stakeholders the partners of this project will initiate a strong coordination and support action to build a pertinent European Nanomedicine community involving all key players necessary to define the resources, gaps and needs for development and implementation of nanomedical research into marketable innovations to be used by doctors for the benefit of patients. The implementation concepts will also target the initiation of Public Private Partnerships for the creation of novel infrastructures and innovative funding programmes.Nanomedicine research is growing fast in many countries. Therefore, the project consortium will initiate international collaborations in the Nanomedicine area, especially the coordination of international regulation of Nanomedicine products.The partners involved in the project represent major European networks combining academia, industry, clinicians and public authorities. Based on this strong partnership and after integration of further national and European initiatives the output of this support action will be a strong, established partnership of relevant stakeholders in identified key areas of Nanomedicine with new concepts for translation of nanomedical innovations into clinical practice and efficient and transparent communication channels. This will make Nanomedicine an important contributor to the future European healthcare system with a beneficial impact on improved treatment for patients and on social challenges such as ageing population.
Get Access to the 1st Network for European Cooperation